Rh&Life, first subject included in the study
Two hundred pregnant women to be enrolled over five countries
Patients at the center of Neuromuscular Disorders Day
Kedrion has confirmed that it will support the initiative this year also
KIDCARES10, first patient enrolled in pediatric PI study
Thirty patients aged 2 to 17 years old to be enrolled over five European countries
Updates on anti-COVID treatment developed by Kamada and Kedrion
Top-line results announced from the phase 1/2 clinical trial in Israel
CARES10 Clinical Trial: last patient treated in the USA
Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients.
Plasma collection, a key step towards Self-Sufficiency in Italy
Paolo Marcucci participates in the Risk Management Forum in Arezzo
Kedrion supports Humanitarian Donation of Factor VIII in Palestine
More accessible treatments: the company continues its commitment, even in the thick of the pandemic
Plasminogen deficiency, diagnosis and treatment of an ultra-rare disease
The featured topic of a SISET webinar with the support of an unconditional contribution from Kedrion
Kedrion is one of the main sponsors of the National SISET Conference
The company sponsors two scientific lectures, a testament to its close ties with the world of medicine and science
